Design, synthesis and characterization of novel small molecular inhibitors of ephrin-B2 binding to EphB4

Biochemical Pharmacology

Volumn 85, Issue 4, 2013, Pages 507-513

  Duggineni, Srinivas ^a   Mitra, Sayantan ^b   Noberini, Roberta ^b   Han, Xiaofeng ^a   Lin, Nan ^a   Xu, Yan ^a   Tian, Wang ^a   An, Jing ^a   Pasquale, Elena B ^b,c   Huang, Ziwei ^a  

^a State University of New York Upstate Medical University: College of Medicine   (United States)

^b BURNHAM INSTITUTE   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Eph receptors; Protein protein interactions; Small molecular inhibitors; Structure based drug design; Tumor angiogenesis

Indexed keywords

EPHRIN B2; EPHRIN RECEPTOR B4; PROTEIN INHIBITOR; TNYL RAW DERIVATIVE; UNCLASSIFIED DRUG;

ARTICLE; CARBOXY TERMINAL SEQUENCE; DRUG DESIGN; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG STRUCTURE; DRUG SYNTHESIS; PRIORITY JOURNAL;

AMINO ACID SEQUENCE; ANTINEOPLASTIC AGENTS; COMPUTER SIMULATION; DRUG DESIGN; EPHRIN-B2; MODELS, MOLECULAR; PROTEIN BINDING; PROTEIN CONFORMATION; RECEPTOR, EPHB4; SIGNAL TRANSDUCTION;

EID: 84872687126     PISSN: 00062952     EISSN: 18732968     Source Type: Journal    
DOI: 10.1016/j.bcp.2012.12.005     Document Type: Article

References (45)

1. E.B. Pasquale Eph-ephrin bidirectional signaling in physiology and disease Cell 133 2008 38 52
2. E.B. Pasquale Eph receptors and ephrins in cancer: bidirectional signaling and beyond Nat Rev Cancer 10 2010 165 180
3. S.R. Kumar, J. Singh, G. Xia, V. Krasnoperov, L. Hassanieh, and E.J. Ley Receptor tyrosine kinase EphB4 is a survival factor in breast cancer Am J Pathol 169 2006 279 293
4. N.K. Noren, G. Foos, C.A. Hauser, and E.B. Pasquale The EphB4 receptor suppresses breast cancer cell tumorigenicity through an Abl-Crk pathway Nat Cell Biol 8 2006 815 825
5. N. Noren, and E.B. Ko Paradoxes of the EphB4 receptor in cancer Cancer Res 67 2007 3994 3997
6. E.B.J. Batlle, H. Begthel, S. Jonkeer, A. Gregorieff, M. van de Born, and N. Malats EphB receptor activity suppresses colorectal cancer progression Nature 435 2005 1126 1130
7. S.A. Stephenson, S. Slomka, E.L. Douglas, P.J. Hewett, and J.E. Hardingham Receptor protein tyrosine kinase EphB4 is up-regulated in colon cancer BMC Mol Biol 2 2001 15
8. G. Xia, S.R. Kumar, J.P. Stein, J. Singh, V. Krasnoperov, and S. Zhu EphB4 receptor tyrosine kinase is expressed in bladder cancer and provides signals for cell survival Oncogene 25 2006 769 780
9. Y.C. Lee, J.R. Perren, E.L. Douglas, M.P. Raynor, M.A. Bartley, and P.G. Bardy Investigation of the expression of the EphB4 receptor tyrosine kinase in prostate carcinoma BMC Cancer 5 2005 1
10. G. Xia, S.R. Kumar, R. Masood, S. Zhu, R. Reddy, and V. Krasnoperov EphB4 expression and biological significance in prostate cancer Cancer Res 65 2005 4623 4632
11. S.R. Kumar, R. Masood, W.A. Spannuth, J. Singh, J. Scehnet, and G. Kleiber The receptor tyrosine kinase EphB4 is overexpressed in ovarian cancer, provides survival signals and predicts poor outcome Br J Cancer 96 2007 1083 1091
12. N.Y. Yang, E.B. Pasquale, L.B. Owen, and I.M. Ethell The EphB4 receptor-tyrosine kinase promotes the migration of melanoma cells through Rho-mediated actin cytoskeleton reorganization J Biol Chem 281 2006 32574 32586
13. R. Masood, S.R. Kumar, U.K. Sinha, D.L. Crowe, V. Krasnoperov, and R.K. Reddy EphB4 provides survival advantage to squamous cell carcinoma of the head and neck Int J Cancer 119 2006 1236 1248
14. N.Y. Yang, P. Lopez-Bergami, J.S. Goydos, D. Yip, A.M. Walker, and E.B. Pasquale The EphB4 receptor promotes the growth of melanoma cells expressing the ephrin-B2 ligand Pigment Cell Melanoma Res 23 2010 684 687
15. Z. Xiao, R. Carrasco, K. Kinneer, D. Sabol, B. Jallal, and S. Coats EphB4 promotes or suppresses Ras/MEK/ERK pathway in a context-dependent manner: implications for EphB4 as a cancer target Cancer Biol Ther 13 2012 630 637
16. T. Fuller, T. Korff, A. Kilian, G. Dandekar, and H.G. Augustin Forward EphB4 signaling in endothelial cells controls cellular repulsion and segregation from ephrinB2 positive cells J Cell Sci 116 2003 2461 2470
17. M. Heroult, F. Schaffner, and H.G. Augustin Eph receptor and ephrin ligand-mediated interactions during angiogenesis and tumor progression Exp Cell Res 312 2006 642 650
18. S. Kuijper, C.J. Turner, and R.H. Adams Regulation of angiogenesis by Eph-ephrin interactions Trends Cardiovasc Med 17 2007 145 151
19. G. Martiny-Baron, T. Korff, F. Schaffner, N. Esser, S. Eggstein, and D. Marme Inhibition of tumor growth and angiogenesis by soluble EphB4 Neoplasia 6 2004 248 257
20. S.S. Foo, C.J. Turner, S. Adams, A. Compagni, D. Aubyn, and N. Kogata Ephrin-B2 controls cell motility and adhesion during blood-vessel-wall assembly Cell 124 2006 161 173
21. N.K. Noren, M. Lu, A.L. Freeman, M. Koolpe, and E.B. Pasquale Interplay between EphB4 on tumor cells and vascular ephrin-B2 regulates tumor growth Proc Natl Acad Sci USA 101 2004 5583 5588
22. O. Salvucci, D. Maric, M. Economopoulou, S. Sakakibara, S. Merlin, and A. Follenzi EphrinB reverse signaling contributes to endothelial and mural cell assembly into vascular structures Blood 114 2009 1707 1716
23. S. Sawamiphak, S. Seidel, C.L. Essmann, G.A. Wilkinson, M.E. Pitulescu, and T. Acker Ephrin-B2 regulates VEGFR2 function in developmental and tumour angiogenesis Nature 465 2010 487 491
24. J.J. Steinle, C.J. Meininger, U. Chowdhury, G. Wu, and H.J. Granger Role of ephrin B2 in human retinal endothelial cell proliferation and migration Cell Signal 15 2003 1011 1017
25. Y. Wang, M. Nakayama, M.E. Pitulescu, T.S. Schmidt, M.L. Bochenek, and A. Sakakibara Ephrin-B2 controls VEGF-induced angiogenesis and lymphangiogenesis Nature 465 2010 483 486
26. V. Krasnoperov, S.R. Kumar, E. Ley, X. Li, J. Scehnet, and R. Liu Novel EphB4 monoclonal antibodies modulate angiogenesis and inhibit tumor growth Am J Pathol 176 2010 2029 2038
27. N. Kertesz, V. Krasnoperov, R. Reddy, L. Leshanski, S.R. Kumar, and S. Zozulya The soluble extracellular domain of EphB4 (sEphB4) antagonizes EphB4-EphrinB2 interaction, modulates angiogenesis, and inhibits tumor growth Blood 107 2006 2330 2338
28. J.S. Scehnet, E.J. Ley, V. Krasnoperov, R. Liu, P.K. Manchanda, and E. Sjoberg The role of Ephs, Ephrins, and growth factors in Kaposi sarcoma and implications of EphrinB2 blockade Blood 113 2009 254 263
29. R. Noberini, I. Lamberto, and E.B. Pasquale Targeting Eph receptors with peptides and small molecules: progress and challenges Semin Cell Dev Biol 1 2012 51 57
30. D.C. Fry, and L.T. Vassilev Targeting protein-protein interactions for cancer therapy J Mol Med 83 2005 955 963
31. J.A. Wells, and C.L. McClendon Reaching for high-hanging fruit in drug discovery at protein-protein interfaces Nature 450 2007 1001 1009
32. Z. Huang Structural chemistry and therapeutic intervention of protein-protein interactions in immune response, human immunodeficiency virus entry, and apoptosis Pharmacol Ther 86 2000 201 215
33. Z. Huang The chemical biology of apoptosis. Exploring protein-protein interactions and the life and death of cells with small molecules Chem Biol 9 2002 059 72
34. M.R. Arkin, and A. Whitty The road less traveled: modulating signal transduction enzymes by inhibiting their protein-protein interactions Curr Opin Chem Biol 13 2009 284 290
35. M. Tognolini, C. Giorgio, I. Hassan Mohamed, Barocelli, L. Calani, and E. Reynaud Perturbation if the EphA2-Ephrin A1 system in human prostate cancer cells by colonic (poly) phenol catabolites J Agric Food Chem 60 2012 8877 8884
36. M. Tognolini, M. Incerti, I. Hassan-Mohamed, C. Giorgio, S. Russo, and R. Bruni Structure-activity relationships and mechanism of action of Eph-ephrin antagonists: interaction of cholanic acid with the EphA2 receptor ChemMedChem 7 2012 1071 1083
37. A. Petty, E. Myshkin, H. Qin, G. Guo, H. Miao, and G.P. Tochtrop A small molecule agonist of EphA2 receptor tyrosine kinase inhibits tumor cell migration in vitro and prostate cancer metastasis in vivo PLoS ONE 7 2012 e42120
38. R. Noberini, M. Koople, I. Lamberto, and E.B. Pasquale Inhibition of Eph receptor-ephrin ligand interaction by tea polyphenols Pharmacol Res 66 2012 363 373
39. M. Koolpe, R. Burgess, M. Dail, and E.B. Pasquale EphB receptor-binding peptides identified by phage display enable design of an antagonist with ephrin-like affinity J Biol Chem 280 2005 17301 17311
40. R. Noberini, S. Mitra, O. Salvucci, F. Valencia, S. Duggineni, and N. Prigozhina PEGylation potentiates the effectiveness of an antagonistic peptide that tragets the EphB4 receptor with nanomolar affinity PLoS ONE 6 2012 e29611
41. J. Berger, J. Hauber, R. Hauber, R. Geiger, and B.R. Cullen Secreted placental alkaline phosphatase: a powerful new quantitative indicator of gene expression in eukaryotic cells Gene 66 1988 1 10
42. B.R. Cullen Utility of the secreted placental alkaline phosphatase reporter enzyme Methods Enzymol 326 2000 159 164
43. J.G. Flanagan, H.J. Cheng, D.A. Feldheim, M. Hattori, Q. Lu, and P. Vanderhaeghen Alkaline phosphatase fusions of ligands or receptors as in situ probes for staining of cells, tissues, and embryos Methods Enzymol 327 2000 19 35
44. J.E. Chrencik, A. Brooun, M.I. Recht, M.L. Kraus, M. Koolpe, and A.R. Kolatkar Structure and thermodynamic characterization of the EphB4/Ephrin-B2 antagonist peptide complex reveals the determinants for receptor specificity Structure 14 2006 321 330
45. C.W. Tornøe, C. Christensen, and M. Meldal Peptidotriazoles on solid phase: [1,2,3]-triazoles by regiospecific copper(i)-catalyzed 1,3-dipolar cycloadditions of terminal alkynes to azides J Org Chem 67 2002 3057 3064